How to buy ImmuPharma shares | 12.802p

Own ImmuPharma shares in just a few minutes.

Posted

Fact checked

ImmuPharma plc (IMM) is a leading biotechnology business based in the UK. It opened the day at 13.305p after a previous close of 13.25p. During the day the price has varied from a low of 12.6p to a high of 13.65p. The latest price was 12.802p (25 minute delay). ImmuPharma is listed on the London Stock Exchange (LSE) and employs 17 staff. All prices are listed in pence sterling.

How to buy shares in ImmuPharma

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: IMM in this case.
  5. Research ImmuPharma shares. The platform should provide the latest information available.
  6. Buy your ImmuPharma shares. It's that simple.

How has Coronavirus impacted ImmuPharma's share price?

Since the stock market crash in March caused by coronavirus, ImmuPharma's share price has had significant negative movement.

Its last market close was 14.35p, which is 10.31% down on its pre-crash value of 16p and 104.71% up on the lowest point reached during the March crash when the shares fell as low as 7.01p.

If you had bought £1,000 worth of ImmuPharma shares at the start of February 2020, those shares would have been worth £623.98 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,059.04.

ImmuPharma share price

Use our graph to track the performance of IMM stocks over time.

ImmuPharma shares at a glance

Information last updated 2020-07-02.
Open13.305p
High13.65p
Low12.6p
Close12.802p
Previous close13.25p
Change -0.448p
Change % -3.381%
Volume 407,725
Information last updated 2020-07-12.
52-week range6.91p - 34p
50-day moving average 14.7022p
200-day moving average 13.6957p
Wall St. target price5p
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) -5.1p
Fineco

Get your first 50 trades commission free with Fineco

Fees apply. Your capital is at risk.

  • Market leading platform
  • No minimum deposit, no conversion fee, no monthly fee
  • Your first 50 share trades are free until 30/09/2020
Promoted

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Your first 50 trades are free with Fineco, until 30/09/2020. T&Cs apply. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund & Share Account
£11.95
£5.95
Transfer out fee
Hargreaves Lansdown is the UK's biggest wealth manager, with the depth of features you'd expect from an established platform. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
eToro is good for social trading - letting you mirror the portfolios of other traders. Capital at risk. 0% commission but other fees may apply.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
£100 or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
£25/month
Over 2,500 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
Moneyfarm Pension
Moneyfarm Pension
0.35%-0.75%
7 funds
£1,500 (initial investment)
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy ImmuPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

ImmuPharma price performance over time

Historical closes compared with the last close of 12.802p

1 week (2020-07-06) -3.38%
1 month (2020-06-12) -17.54%
3 months (2020-04-09) 26.44%
6 months (2020-01-13) -18.20%
1 year (2019-07-12) 25.05%
2 years (2018-07-13) -41.28%
3 years (2017-07-13) -77.93%
5 years (2015-07-13) -67.38%

ImmuPharma financials

Revenue TTM £77,925
Gross profit TTM £77,925
Return on assets TTM -54.31%
Return on equity TTM -95%
Profit margin 0%
Book value 0.031p
Market capitalisation £25.3 million

TTM: trailing 12 months

ImmuPharma share dividends

We're not expecting ImmuPharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

ImmuPharma share price volatility

Over the last 12 months, ImmuPharma's shares have ranged in value from as little as 6.91p up to 34p. A popular way to gauge a stock's volatility is its "beta".

IMM.LSE volatility(beta: 0.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while ImmuPharma's is 0.6529. This would suggest that ImmuPharma's shares are less volatile than average (for this exchange).

ImmuPharma overview

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site